Science Saru will return with a third season of “Dan Da Dan” airing in 2027, the studio revealed during Jump Festa 2026 on Dec. 21, revealing a new key visual for the supernatural comedy series. The ...

FBI Deputy Director Dan Bongino is leaving the bureau in January after speculation rose this week concerning his departure. "I will be leaving my position with the FBI in January," Bongino wrote in an ...

FBI Deputy Director Dan Bongino is stepping down in January. President Donald Trump said that Bongino "did a great job," adding, "I think he wants to go back to his show." Bongino, the No. 2 FBI ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Chef Jon Sybert and his wife, Jill Tyler – alums of now-closed fine dining relics Komi and Little Serow – debuted Tail Up Goat in 2016, and went on to receive (and maintain) its star when the D.C.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Dan Reynolds is the instantly recognizable frontman for Imagine Dragons. He was married to fellow singer Aja Volkman for ten years. They share four children, including a set of twins. Dan is currently ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...